JP5722901B2 - グルコースの吸収および排泄の指標としてのα−メチルグルコシド（ＡＭＧ）の使用 - Google Patents
グルコースの吸収および排泄の指標としてのα−メチルグルコシド（ＡＭＧ）の使用 Download PDFInfo
- Publication number
- JP5722901B2 JP5722901B2 JP2012529847A JP2012529847A JP5722901B2 JP 5722901 B2 JP5722901 B2 JP 5722901B2 JP 2012529847 A JP2012529847 A JP 2012529847A JP 2012529847 A JP2012529847 A JP 2012529847A JP 5722901 B2 JP5722901 B2 JP 5722901B2
- Authority
- JP
- Japan
- Prior art keywords
- amg
- animal
- sample
- amount
- glucose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title claims description 54
- 239000008103 glucose Substances 0.000 title claims description 54
- 238000010521 absorption reaction Methods 0.000 title claims description 19
- HOVAGTYPODGVJG-ZFYZTMLRSA-N methyl alpha-D-glucopyranoside Chemical compound CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HOVAGTYPODGVJG-ZFYZTMLRSA-N 0.000 title claims description 19
- 230000029142 excretion Effects 0.000 title claims description 18
- 241001465754 Metazoa Species 0.000 claims description 70
- 238000000034 method Methods 0.000 claims description 40
- 210000002700 urine Anatomy 0.000 claims description 30
- 210000002381 plasma Anatomy 0.000 claims description 29
- 108091006277 SLC5A1 Proteins 0.000 claims description 27
- 102000058090 Sodium-Glucose Transporter 1 Human genes 0.000 claims description 27
- 230000002496 gastric effect Effects 0.000 claims description 27
- 239000003112 inhibitor Substances 0.000 claims description 21
- 230000000694 effects Effects 0.000 claims description 18
- 241000700159 Rattus Species 0.000 claims description 16
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 15
- 210000003734 kidney Anatomy 0.000 claims description 12
- 239000011734 sodium Substances 0.000 claims description 11
- 229940121377 sodium-glucose co-transporter inhibitor Drugs 0.000 claims description 11
- 108091052347 Glucose transporter family Proteins 0.000 claims description 9
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 claims description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 229910052708 sodium Inorganic materials 0.000 claims description 8
- 241000282472 Canis lupus familiaris Species 0.000 claims description 7
- 241000699800 Cricetinae Species 0.000 claims description 7
- 241000282412 Homo Species 0.000 claims description 7
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 claims description 7
- 230000001419 dependent effect Effects 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 210000005095 gastrointestinal system Anatomy 0.000 claims description 6
- 241000700198 Cavia Species 0.000 claims description 5
- 241000699670 Mus sp. Species 0.000 claims description 5
- 241000282887 Suidae Species 0.000 claims description 5
- 241000700199 Cavia porcellus Species 0.000 claims 2
- 241000699666 Mus <mouse, genus> Species 0.000 claims 2
- 241000288906 Primates Species 0.000 claims 2
- 239000000523 sample Substances 0.000 description 32
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 19
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 16
- 206010012601 diabetes mellitus Diseases 0.000 description 15
- 230000009102 absorption Effects 0.000 description 14
- 238000011282 treatment Methods 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 229940125782 compound 2 Drugs 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 229940125904 compound 1 Drugs 0.000 description 10
- 238000001514 detection method Methods 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 238000005481 NMR spectroscopy Methods 0.000 description 9
- 102000000070 Sodium-Glucose Transport Proteins Human genes 0.000 description 9
- 108010080361 Sodium-Glucose Transport Proteins Proteins 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 229940125396 insulin Drugs 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 102000004877 Insulin Human genes 0.000 description 7
- 108090001061 Insulin Proteins 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 201000001421 hyperglycemia Diseases 0.000 description 7
- 239000006166 lysate Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 206010022489 Insulin Resistance Diseases 0.000 description 6
- 229940126902 Phlorizin Drugs 0.000 description 6
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000000670 limiting effect Effects 0.000 description 6
- IOUVKUPGCMBWBT-UHFFFAOYSA-N phloridzosid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-UHFFFAOYSA-N 0.000 description 6
- IOUVKUPGCMBWBT-GHRYLNIYSA-N phlorizin Chemical compound O[C@@H]1[C@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-GHRYLNIYSA-N 0.000 description 6
- 235000019139 phlorizin Nutrition 0.000 description 6
- 210000000512 proximal kidney tubule Anatomy 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 230000006377 glucose transport Effects 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 230000030558 renal glucose absorption Effects 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 108010078791 Carrier Proteins Proteins 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 208000031773 Insulin resistance syndrome Diseases 0.000 description 4
- 208000001145 Metabolic Syndrome Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000012131 assay buffer Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000002218 hypoglycaemic effect Effects 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 4
- 229960003105 metformin Drugs 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 229940127017 oral antidiabetic Drugs 0.000 description 4
- 201000009104 prediabetes syndrome Diseases 0.000 description 4
- 238000009097 single-agent therapy Methods 0.000 description 4
- 239000008223 sterile water Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000032258 transport Effects 0.000 description 4
- 210000005239 tubule Anatomy 0.000 description 4
- 208000002705 Glucose Intolerance Diseases 0.000 description 3
- 101000716688 Homo sapiens Sodium/glucose cotransporter 1 Proteins 0.000 description 3
- 101000716682 Homo sapiens Sodium/glucose cotransporter 2 Proteins 0.000 description 3
- 208000013016 Hypoglycemia Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229940123464 Thiazolidinedione Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 150000002303 glucose derivatives Chemical class 0.000 description 3
- 102000052194 human SLC5A1 Human genes 0.000 description 3
- 102000052543 human SLC5A2 Human genes 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 238000011221 initial treatment Methods 0.000 description 3
- 210000001630 jejunum Anatomy 0.000 description 3
- 208000017169 kidney disease Diseases 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- HOVAGTYPODGVJG-UHFFFAOYSA-N methyl beta-galactoside Natural products COC1OC(CO)C(O)C(O)C1O HOVAGTYPODGVJG-UHFFFAOYSA-N 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 206010036067 polydipsia Diseases 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 2
- 206010004716 Binge eating Diseases 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 208000032841 Bulimia Diseases 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 229920003091 Methocel™ Polymers 0.000 description 2
- 238000012879 PET imaging Methods 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 229940100389 Sulfonylurea Drugs 0.000 description 2
- QPXCWKLWAQHVKP-CHBZFOKHSA-M [2H]C([2H])(C)C([2H])([2H])[Si](C)(C)C([2H])([2H])S(=O)(=O)[O-].[Na+] Chemical compound [2H]C([2H])(C)C([2H])([2H])[Si](C)(C)C([2H])([2H])S(=O)(=O)[O-].[Na+] QPXCWKLWAQHVKP-CHBZFOKHSA-M 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 201000010390 abdominal obesity-metabolic syndrome 1 Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000002266 amputation Methods 0.000 description 2
- 229940127003 anti-diabetic drug Drugs 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 208000014679 binge eating disease Diseases 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 208000028208 end stage renal disease Diseases 0.000 description 2
- 201000000523 end stage renal failure Diseases 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 230000002641 glycemic effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 208000011661 metabolic syndrome X Diseases 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 238000009206 nuclear medicine Methods 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- VGEREEWJJVICBM-UHFFFAOYSA-N phloretin Chemical compound C1=CC(O)=CC=C1CCC(=O)C1=C(O)C=C(O)C=C1O VGEREEWJJVICBM-UHFFFAOYSA-N 0.000 description 2
- 230000000291 postprandial effect Effects 0.000 description 2
- 230000036278 prepulse Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- HOVAGTYPODGVJG-UVSYOFPXSA-N (3s,5r)-2-(hydroxymethyl)-6-methoxyoxane-3,4,5-triol Chemical compound COC1OC(CO)[C@@H](O)C(O)[C@H]1O HOVAGTYPODGVJG-UVSYOFPXSA-N 0.000 description 1
- ZWTDXYUDJYDHJR-UHFFFAOYSA-N (E)-1-(2,4-dihydroxyphenyl)-3-(2,4-dihydroxyphenyl)-2-propen-1-one Natural products OC1=CC(O)=CC=C1C=CC(=O)C1=CC=C(O)C=C1O ZWTDXYUDJYDHJR-UHFFFAOYSA-N 0.000 description 1
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000034534 Cotransporters Human genes 0.000 description 1
- 108020003264 Cotransporters Proteins 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 241000162069 Fejervarya cancrivora Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 102000042092 Glucose transporter family Human genes 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- YQHMWTPYORBCMF-UHFFFAOYSA-N Naringenin chalcone Natural products C1=CC(O)=CC=C1C=CC(=O)C1=C(O)C=C(O)C=C1O YQHMWTPYORBCMF-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000016222 Pancreatic disease Diseases 0.000 description 1
- 108010005991 Pork Regular Insulin Proteins 0.000 description 1
- 208000001280 Prediabetic State Diseases 0.000 description 1
- 101100095088 Rattus norvegicus Slc5a2 gene Proteins 0.000 description 1
- 108091006299 SLC2A2 Proteins 0.000 description 1
- 102100037202 Sodium/myo-inositol cotransporter 2 Human genes 0.000 description 1
- 101710090560 Sodium/myo-inositol cotransporter 2 Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 230000009118 appropriate response Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- FCPVYOBCFFNJFS-LQDWTQKMSA-M benzylpenicillin sodium Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 FCPVYOBCFFNJFS-LQDWTQKMSA-M 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000001258 dyslipidemic effect Effects 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 238000011597 hartley guinea pig Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 238000012613 in situ experiment Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229940035734 metformin and sulfonylureas Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24257009P | 2009-09-15 | 2009-09-15 | |
| US61/242,570 | 2009-09-15 | ||
| PCT/US2010/048752 WO2011034846A1 (en) | 2009-09-15 | 2010-09-14 | Use of alpha-methylglucoside (amg) as an indicator for glucose absorption and excretion |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013504769A JP2013504769A (ja) | 2013-02-07 |
| JP5722901B2 true JP5722901B2 (ja) | 2015-05-27 |
Family
ID=42983318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012529847A Expired - Fee Related JP5722901B2 (ja) | 2009-09-15 | 2010-09-14 | グルコースの吸収および排泄の指標としてのα−メチルグルコシド（ＡＭＧ）の使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8147801B2 (OSRAM) |
| EP (1) | EP2478357A1 (OSRAM) |
| JP (1) | JP5722901B2 (OSRAM) |
| CN (1) | CN102597770B (OSRAM) |
| AU (1) | AU2010295722B2 (OSRAM) |
| IN (1) | IN2012DN02711A (OSRAM) |
| WO (1) | WO2011034846A1 (OSRAM) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3714905B1 (en) * | 2017-11-21 | 2025-01-22 | Solvex Limited Liability Company | Preparation for magnetic resonance diagnostics for oncological diseases, comprising deuterated 3-o-methylglucose, and diagnostic method using said preparation |
| JP7570663B2 (ja) | 2020-07-22 | 2024-10-22 | 国立大学法人群馬大学 | 糖尿病、肥満および／または脂肪肝に対する新規診断マーカーおよび新規治療用組成物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4540475B2 (ja) * | 2002-08-08 | 2010-09-08 | キッセイ薬品工業株式会社 | ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体 |
| ZA200501094B (en) * | 2002-08-08 | 2006-10-25 | Kissei Pharmaceutical | Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof |
| JP2005015460A (ja) * | 2002-10-29 | 2005-01-20 | Takeda Chem Ind Ltd | Ｓｇｌｔホモログ用途 |
| EP1557178A4 (en) * | 2002-10-29 | 2009-07-22 | Takeda Pharmaceutical | USE OF SGLT HOMOLOG |
| CN1771334A (zh) * | 2003-03-07 | 2006-05-10 | 施瑞修德制药公司 | 用于确定肿瘤对抗肿瘤药剂的治疗的敏感性的方法 |
| EA010655B1 (ru) * | 2003-08-01 | 2008-10-30 | Янссен Фармацевтика Н.В. | Замещенные индазол-о-глюкозиды |
| EA015104B1 (ru) | 2003-08-01 | 2011-06-30 | Мицубиси Танабе Фарма Корпорейшн | Новые соединения, обладающие ингибирующей активностью в отношении натрийзависимого транспортера |
| JP2005139093A (ja) * | 2003-11-05 | 2005-06-02 | Nichirei Corp | グルコース吸収阻害剤およびその製造方法 |
| AR053329A1 (es) * | 2005-01-31 | 2007-05-02 | Tanabe Seiyaku Co | Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt) |
| TWI418556B (zh) | 2006-07-27 | 2013-12-11 | Mitsubishi Tanabe Pharma Corp | 吲哚衍生物 |
| TW200904454A (en) | 2007-03-22 | 2009-02-01 | Bristol Myers Squibb Co | Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof |
| JP2009155212A (ja) * | 2007-12-25 | 2009-07-16 | Taisho Pharmaceutical Co Ltd | Ｃ−フェニル１−チオグルシト−ル化合物を有効成分とする糖尿病治療剤 |
-
2010
- 2010-09-14 IN IN2711DEN2012 patent/IN2012DN02711A/en unknown
- 2010-09-14 CN CN201080051671.0A patent/CN102597770B/zh not_active Expired - Fee Related
- 2010-09-14 AU AU2010295722A patent/AU2010295722B2/en not_active Ceased
- 2010-09-14 EP EP10755292A patent/EP2478357A1/en not_active Withdrawn
- 2010-09-14 WO PCT/US2010/048752 patent/WO2011034846A1/en not_active Ceased
- 2010-09-14 US US12/881,695 patent/US8147801B2/en not_active Expired - Fee Related
- 2010-09-14 JP JP2012529847A patent/JP5722901B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US8147801B2 (en) | 2012-04-03 |
| EP2478357A1 (en) | 2012-07-25 |
| US20110065200A1 (en) | 2011-03-17 |
| AU2010295722B2 (en) | 2015-04-16 |
| AU2010295722A1 (en) | 2012-04-12 |
| IN2012DN02711A (OSRAM) | 2015-09-11 |
| WO2011034846A1 (en) | 2011-03-24 |
| JP2013504769A (ja) | 2013-02-07 |
| CN102597770B (zh) | 2016-08-10 |
| CN102597770A (zh) | 2012-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wright et al. | Biology of human sodium glucose transporters | |
| Ryder et al. | Use of a novel impermeable biotinylated photolabeling reagent to assess insulin-and hypoxia-stimulated cell surface GLUT4 content in skeletal muscle from type 2 diabetic patients. | |
| Wright et al. | Novel and unexpected functions of SGLTs | |
| JP6175172B2 (ja) | 筋萎縮を阻害するための方法 | |
| Dixit et al. | Effects of CaMKII-mediated phosphorylation of ryanodine receptor type 2 on islet calcium handling, insulin secretion, and glucose tolerance | |
| Nagy et al. | Hyaluronan levels are increased systemically in human type 2 but not type 1 diabetes independently of glycemic control | |
| ES2955984T3 (es) | Factor de diferenciación de crecimiento 15 como biomarcador para metformina | |
| US20150247839A1 (en) | Cmpf as a biomarker for diabetes and associated methods | |
| Argade et al. | An evaluation of Tamm–Horsfall protein glycans in kidney stone formers using novel techniques | |
| AU2017301949B2 (en) | Compounds, reagents, and uses thereof | |
| US20140271474A1 (en) | Inhibitor probes for imaging sodium-glucose cotransporters in health and disease | |
| Yokoyama et al. | Serum and urinary concentrations of heparan sulfate in patients with diabetic nephropathy | |
| Zhu et al. | Association of serum PSP/REG Iα with renal function in type 2 diabetes mellitus | |
| JP5722901B2 (ja) | グルコースの吸収および排泄の指標としてのα−メチルグルコシド（ＡＭＧ）の使用 | |
| JP2008537928A (ja) | キサンツレン酸誘導体医薬組成物およびそれに関連する方法 | |
| JPWO2014088118A1 (ja) | 心病変マーカー及びその利用 | |
| WO2016040643A1 (en) | Amyotrophic lateral sclerosis (als) biomarkers and uses thereof | |
| Hussein | The journey of Sotagliflozin: from its status as a withdrawn candidate for the treatment of diabetes mellitus, to its repurposing as a groundbreaking drug for the management of heart failure. | |
| EP1346227B1 (en) | Detection of advanced glycation endproducts in a cerebrospinal fluid sample | |
| Hummel et al. | Glucose reabsorption in the kidney | |
| Keshishyan | Glomerular Glycosylation Abnormalities in Nephrotic Syndrome | |
| CN120114450A (zh) | 一种1-脱氧野尻霉素在激活线粒体atp合酶改善糖尿病心肌病心肌功能上的应用 | |
| Vallon | Articles in PresS. Am J Physiol Cell Physiol (November 3, 2010). doi: 10.1152/ajpcell. 00444.2010 | |
| Joe et al. | Sexual dimorphism in the progression of type 2 diabetic kidney disease in T2DN rats | |
| JP2018203679A (ja) | 新規機能タンパク質及びそれを用いた老化抑制方法及び薬剤、並びに老化抑制薬剤候補物質スクリーニング方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130725 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130725 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20140326 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140402 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140701 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140723 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141015 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141105 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150130 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150225 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150326 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5722901 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |